ArticleCancer research2017

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Triparna Sen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.